<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bexagliflozin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bexagliflozin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bexagliflozin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140690" href="/d/html/140690.html" rel="external">see "Bexagliflozin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58504274"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brenzavvy</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57831007"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;</li>
<li>
                        Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F57850007"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Correct hypovolemia, if present, prior to initiating treatment. May require a gradual dose reduction of insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>20 mg once daily in the morning.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57850009"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients on dialysis: Impact of hemodialysis is not known; use is not recommended (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F57850010"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F57850008"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58119735"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute Kidney Injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of acute kidney injury (AKI) have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (specifically canagliflozin and dapagliflozin), including cases that have required hospitalization and dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). In addition, <b>increased serum creatinine</b> and <b>decreased estimated GFR (eGFR)</b> have been reported with bexagliflozin. In one clinical study in patients with type 2 diabetes mellitus and stage 3a/3b chronic kidney disease, a reversible increase in serum creatinine (+0.08 mg/dL) and decrease in eGFR (-2.41 mL/minute/1.73 m<sup>2</sup>) was observed in patients treated with bexagliflozin. AKI events were rarely reported in this study and all events were defined as stage I AKI. Long-term studies of other SGLT2 inhibitors suggest an overall reduction in the risk of AKI and kidney-related serious adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31101403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31101403'])">Ref</a></span>). As evidence mounts for positive effects of these agents on long-term kidney outcomes and possible reduction in the incidence of AKI, clinicians will need to weigh the potential risk of AKI with the overall benefit of these agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32239659','lexi-content-ref-31050116','lexi-content-ref-32970396','lexi-content-ref-35977807','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-30415602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32239659','lexi-content-ref-31050116','lexi-content-ref-32970396','lexi-content-ref-35977807','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-30415602'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. SGLT2 inhibition causes increased excretion of glucose and sodium, thereby resulting in an osmotic diuresis; the subsequent hyperosmolarity and volume contraction may increase the risk of AKI. Glucose in the urine may be reabsorbed by glucose transporters in exchange for uric acid, resulting in uricosuria and associated crystal-dependent and -independent damage. Lastly, SGLT2 inhibition results in increased fructose generation; the metabolism of fructose may lead to increased uric acid, oxidative stress, and the release of chemokines, thus causing local tubular injury and inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31050116','lexi-content-ref-27847389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31050116','lexi-content-ref-27847389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">On the other hand, bexagliflozin may confer some protection against AKI. Proposed mechanisms based on animal studies regarding the beneficial effects of SGLT2 inhibition on AKI include improved kidney cortical oxygen tension, tubular cell integrity, and tubular albumin reabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26041448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26041448'])">Ref</a></span>); in addition, improved cardiac function may be related to improved kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30939483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30939483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in one study, increases in serum creatinine and decreases in eGFR were seen within 6 weeks of bexagliflozin initiation, which tended to stabilize after ~12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31101403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31101403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for AKI (eg, hypovolemia, chronic kidney insufficiency, heart failure, use of concomitant medications [eg, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs])</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone fracture</b> has been reported with bexagliflozin in clinical studies in certain patient populations (patients with type 2 diabetes and stage 3a/3b chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31101403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31101403'])">Ref</a></span>) and patients with type 2 diabetes mellitus with either established cardiovascular (CVD) or increased CVD risk). In the overall population, longer-term data may be necessary to clarify risk of bone fractures with bexagliflozin.</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Delayed; fractures were observed within the first 6 months of therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension/volume depletion</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium glucose cotransporter 2 (SGLT2) inhibitors, including bexagliflozin, may cause events consistent with hypovolemia, including symptomatic hypotension, syncope, and dehydration. In bexagliflozin clinical trials, systolic blood pressure (SBP) was reduced by -3.8 to -12.9 mm Hg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31101403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31101403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Inhibition of SGLT2 causes an increase in the excretion of glucose and sodium, thereby resulting in an osmotic diuresis and intravascular volume contraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28546454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28546454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; reduced SBP has been observed within the first 6 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31101403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31101403'])">Ref</a></span>); timing is impacted by volume status (eg, reduced oral intake, fluid losses) and concomitant use of medications known to impact volume status or blood pressure (eg, diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of antihypertensives (eg, diuretics, ACE inhibitors, ARBs)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting low systolic blood pressure</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced oral intake or increased fluid losses</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including bexagliflozin, have been associated with increased risk of genitourinary fungal infection (eg, <b>vaginal mycosis</b>, <b>vulvovaginal candidiasis</b>, vulvovaginitis, candida balanitis, <b>balanoposthitis</b>) and <b>urinary tract infections</b>, including severe cases of <b>urinary tract infection with sepsis</b> and <b>pyelonephritis </b>requiring hospitalization. Additionally, rare but serious and potentially fatal cases of necrotizing fasciitis (perineum) (ie, Fournier gangrene) have been reported with SGLT2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053','lexi-content-ref-FDA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053','lexi-content-ref-FDA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Patients with diabetes are more prone to urinary tract and genital infections, potentially due to glucosuria-induced bacterial growth, increased adherence of bacteria to the uroepithelium, and altered immune function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>). Because SGLT2 inhibitors increase urinary excretion of glucose, it has been hypothesized that these agents further increase the risk of these infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; available literature suggests that increased risk of genital infection may be apparent within the first month of SGLT2 inhibitor therapy and remain elevated throughout the course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30207042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30207042'])">Ref</a></span>); Fournier gangrene may have an average onset of 9 months (range: 5 days to 49 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes and/or uncontrolled hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of these types of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32808541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32808541'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32808541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32808541'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Uncircumcised males (increased risk for genital infections) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23748505'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ketoacidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>ketoacidosis</b> have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, including bexagliflozin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28736981','lexi-content-ref-FDA.2','lexi-content-ref-26294774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28736981','lexi-content-ref-FDA.2','lexi-content-ref-26294774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In some cases, patients have presented with normal or only modestly elevated blood glucose (&lt;250 mg/dL), which can lead to misdiagnosis, prevent timely initiation of treatment, and negatively influence duration of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30728224','lexi-content-ref-28797889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30728224','lexi-content-ref-28797889'])">Ref</a></span>). In addition, SGLT2 inhibitor-mediated increases in urinary glucose loss may persist for several days after discontinuation which may impact duration of illness in patients who develop ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Several mechanisms have been proposed centered on increased ketone body production and reabsorption. Because SGLT2 inhibitors decrease urinary excretion of ketone bodies and decrease blood glucose in an insulin-independent manner, plasma glucose and urine ketone concentrations may be lower than what is typically expected in classic presentations of diabetic ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665','lexi-content-ref-26086329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665','lexi-content-ref-26086329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; timing is often impacted by the onset of metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction [MI], stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with diabetes who are insulin deficient (eg, latent autoimmune diabetes in adults, type 1 diabetes, or some patients with long-standing type 2 diabetes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Metabolically stressful events (eg, surgery, extensive exercise, MI, stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of other risk factors that may predispose a patient to ketoacidosis (eg, pancreatic insulin deficiency, dose decreases or missed doses of insulin, caloric restriction, alcohol abuse, acute febrile illness, surgery, ketogenic diet, volume depletion, or any other extreme stress event)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of pancreatitis or pancreatic surgery</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lower limb amputations</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increase in lower limb amputations has been observed in patients treated with bexagliflozin. In a clinical trial in patients with type 2 diabetes and established cardiovascular disease (CVD) or risk factors for CVD, the incidence of nontraumatic lower limb amputations was 2% in the bexagliflozin-treated population, compared to 1.2% in placebo-treated patients. Amputations observed involved the toe, midfoot, or less frequently the leg (above or below the knee); lower limb infections, gangrene, ischemia, and osteomyelitis were the most common precipitating factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for amputation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers, cardiovascular disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32843476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32843476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32843476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32843476'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57840906"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and may include percentages reported as part of a combination regimen with metformin.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (2%), increased LDL cholesterol (2%), increased thirst (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Diuresis (7%; including nocturia, polyuria, urinary frequency, and urinary urgency), male genital disease (2%; including balanoposthitis, localized fungal infection [genital], and tinea [tinea cruris]), urinary tract infection (6%; including urinary tract infection with sepsis)<span class="lexi-table-link-container"> (<a aria-label="Urinary Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-urinary-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urinary-tract-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Urinary Tract Infection</span>, vaginal mycosis (6%; including vulvovaginal candidiasis)<span class="lexi-table-link-container"> (<a aria-label="Vaginal Mycosis table link" class="lexi-table-link" data-table-id="lexi-content-vaginal-mycosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vaginal-mycosis')">table 2</a>)</span><span class="table-link" style="display:none;">Vaginal Mycosis</span>, vulvovaginal pruritus (3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urinary Tract Infection" frame="border" id="lexi-content-urinary-tract-infection" rules="all">
<caption style="text-align:left;">
<b>Bexagliflozin: Adverse Reaction: Urinary Tract Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bexagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bexagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">372</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Monotherapy or in combination with metformin</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vaginal Mycosis" frame="border" id="lexi-content-vaginal-mycosis" rules="all">
<caption style="text-align:left;">
<b>Bexagliflozin: Adverse Reaction: Vaginal Mycosis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bexagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bexagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">372</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Monotherapy or in combination with metformin</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased hematocrit (1%), increased hemoglobin (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ketoacidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Allegretti 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased estimated GFR (eGFR) (Allegretti 2019), increased serum creatinine (Allegretti 2019), pyelonephritis</p></div>
<div class="block coi drugH1Div" id="F57831010"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to bexagliflozin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57849993"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy and closely monitor the patient for the duration of therapy; volume depletion and related adverse events (eg, hypotension, orthostatic hypotension, syncope) have occurred. Fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">– Euglycemic diabetic ketoacidosis: Discontinue therapy 3 to 5 days prior to surgery (Bobart 2016). Postoperatively, assess volume status, caloric intake, and need for diabetes treatment and withhold antidiabetic medication if type 2 diabetes is in remission. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes on SGLT2 inhibitors. In some cases, normal or only modestly elevated blood glucose was present (&lt;250 mg/dL) (van Niekerk 2018). Risk factors include significant reduction in insulin, caloric restriction, stress of surgery, and infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Older adults may be predisposed to symptoms related to intravascular volume depletion (eg, hypotension, orthostatic hypotension, dizziness, syncope, dehydration) and renal impairment or failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis or for glycemic control in patients with type 1 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Use of SGLT2 inhibitors is not routinely recommended for glycemic control in hospitalized patients (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Consider temporary discontinuation ≥3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p></div>
<div class="block foc drugH1Div" id="F58504275"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brenzavvy: 20 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p></div>
<div class="block geq drugH1Div" id="F58504273"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F58579180"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bexagliflozin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $13.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Brenzavvy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57850011"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer in the morning without regard to meals. Do not crush or chew.</p></div>
<div class="block meg drugH1Div" id="F57892171"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F214373s001lbl.pdf%23page%3D22&amp;token=Dln4BYzKboyJaTangm1km%2FJ1QiqdcUOVavfoFx5eOL4bznKt8slGyUZtuEi6g3xJoEoty3XYaXl2ajwMyFQ6YPKBKUWHVQIFm8x%2Bj8D%2BrK7kL%2B9T3K%2BD%2BsQVkobZSg5V&amp;TOPIC_ID=140647" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s001lbl.pdf#page=22</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F57831009"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-4em;margin-left:4em;">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p>
<p style="text-indent:-4em;margin-left:6em;">Limitations of use: Not recommended in patients with diabetic ketoacidosis or to improve glycemic control in patients with type 1 diabetes mellitus.</p></div>
<div class="block mst drugH1Div" id="F57849989"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bexagliflozin may be confused with bexarotene.</p>
<p style="text-indent:-2em;margin-left:4em;">Brenzavvy may be confused with Brenzys (Canadian brand name for etanercept).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to increased risk of urogenital infections, especially in women during the first month of use. In addition, a higher risk of euglycemic diabetic ketoacidosis has been observed in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57851911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), UGT1A9; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F57851908"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A9 Inducers: May decrease the serum concentration of Bexagliflozin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57849990"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Sodium-glucose cotransporter 2 inhibitors are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020).</p></div>
<div class="block pri drugH1Div" id="F57849991"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Due to adverse effects on renal development observed in animal studies, the manufacturer does not recommend use during the second and third trimesters of pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than bexagliflozin are currently recommended to treat diabetes mellitus during pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F57849992"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bexagliflozin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, including possible risk to kidney development, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F57850014"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Blood glucose; renal function (baseline and periodically during treatment); volume status (eg, BP, hematocrit, electrolytes); genital mycotic infections and urinary tract infection; necrotizing fasciitis (fever or malaise along with genital or perianal pain, tenderness, erythema, or swelling); hypersensitivity reactions; BP; lower limb and feet (sores, ulcers, infection); signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis by direct measurement of blood ketones and arterial pH (measurement of serum bicarbonate or urinary ketones may not be adequate) (AACE [Handelsman 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA</i>
<i>
<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F57850013"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023], ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F57849996"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.</p></div>
<div class="block phk drugH1Div" id="F57849997"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 262 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily metabolized through UGT1A9 and, to a lesser extent, CYP3A to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak (plasma): 2 to 4 hours; extended to 5 hours (median) if taken after a high-fat, high-calorie meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (51.1%, majority as unchanged drug); urine (40.5%, majority as inactive metabolite).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 19.1 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F57850004"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC is increased in patients with impaired kidney function. In mild (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup>), moderate (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), and severe (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>), bexagliflozin AUC was increased 7%, 34%, and 54%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment: In patients with moderate hepatic impairment (Child-Pugh class B), AUC increased by 28% and C<sub>max</sub> increased by 6.3%.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31101403">
<a name="31101403"></a>Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. <i>Am J Kidney Dis</i>. 2019;74(3):328-337. doi:10.1053/j.ajkd.2019.03.417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31101403/pubmed" id="31101403" target="_blank">31101403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;46(suppl 1):S1-S85. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060053">
<a name="31060053"></a>Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. <i>Ann Intern Med</i>. 2019;170(11):764-769. doi:10.7326/M19-0085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31060053/pubmed" id="31060053" target="_blank">31060053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28736981">
<a name="28736981"></a>Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. <i>Diabetes Metab Res Rev</i>. 2017;33(8):10.1002/dmrr.2924. doi:10.1002/dmrr.2924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28736981/pubmed" id="28736981" target="_blank">28736981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27699391">
<a name="27699391"></a>Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. <i>Ann Intern Med</i>. 2016;165(7):530-532. doi:10.7326/L15-0535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/27699391/pubmed" id="27699391" target="_blank">27699391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brenzavvy.1">
<a name="Brenzavvy.1"></a>Brenzavvy (bexagliflozin) [prescribing information]. Marlborouth, MA: TheracosBio LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32239659">
<a name="32239659"></a>Cahn A, Raz I, Bonaca M, et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes Obes Metab</i>. 2020;22(8):1357-1368. doi:10.1111/dom.14041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32239659/pubmed" id="32239659" target="_blank">32239659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30939483">
<a name="30939483"></a>Chu C, Lu YP, Yin L, Hocher B. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. <i>Kidney Blood Press Res</i>. 2019;44(2):149-157. doi:10.1159/000498963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30939483/pubmed" id="30939483" target="_blank">30939483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728224">
<a name="30728224"></a>Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. <i>Diabetes Care</i>. 2019;42(6):1147-1154. doi:10.2337/dc18-2316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30728224/pubmed" id="30728224" target="_blank">30728224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207042">
<a name="30207042"></a>Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21(2):434-438. doi:10.1111/dom.13531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30207042/pubmed" id="30207042" target="_blank">30207042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28797889">
<a name="28797889"></a>Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights Into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: It's not just euglycemic diabetic ketoacidosis. <i>Can J Diabetes</i>. 2017;41(5):499-503. doi:10.1016/j.jcjd.2017.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28797889/pubmed" id="28797889" target="_blank">28797889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32808541">
<a name="32808541"></a>Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. <i>Ann Pharmacother</i>. 2021;55(4):543-548. doi:10.1177/1060028020951928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32808541/pubmed" id="32808541" target="_blank">32808541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canaglifozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Published June 14, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration. Published December 4, 2015. Updated March 19, 2020. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.3">
<a name="FDA.3"></a>FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Food and Drug Administration. Published August 29, 2018. Updated September 7, 2018. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081590">
<a name="31081590"></a>Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21 Suppl 2:34-42. doi:10.1111/dom.13611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31081590/pubmed" id="31081590" target="_blank">31081590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32843476">
<a name="32843476"></a>Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ</i>. 2020;370:m2812. doi:10.1136/bmj.m2812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32843476/pubmed" id="32843476" target="_blank">32843476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529566">
<a name="24529566"></a>Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. <i>Diabetes Res Clin Pract</i>. 2014;103(3):373-381. doi:10.1016/j.diabres.2013.12.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/24529566/pubmed" id="24529566" target="_blank">24529566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31050116">
<a name="31050116"></a>Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. <i>Diabetes Obes Metab</i>. 2019;21(8):1996-2000. doi:10.1111/dom.13754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31050116/pubmed" id="31050116" target="_blank">31050116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27847389">
<a name="27847389"></a>Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. <i>Nat Rev Nephrol</i>. 2016;12(12):711-712. doi:10.1038/nrneph.2016.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/27847389/pubmed" id="27847389" target="_blank">27847389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27082665">
<a name="27082665"></a>Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. <i>Endocr Pract</i>. 2016;22(6):753-762. doi:10.4158/EP161292.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/27082665/pubmed" id="27082665" target="_blank">27082665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32970396">
<a name="32970396"></a>Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. <i>N Engl J Med</i>. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32970396/pubmed" id="32970396" target="_blank">32970396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35977807">
<a name="35977807"></a>Jongs N, Chertow GM, Greene T, et al; DAPA-CKD Trial Committees and Investigators; Members of the DAPA-CKD Trial Committees and Investigators. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. <i>J Am Soc Nephrol</i>. 2022;33(11):2094-2107. doi:10.1681/ASN.2022030306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/35977807/pubmed" id="35977807" target="_blank">35977807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int.</i> 2020;98(4 suppl):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol</i>
<i>Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28546454">
<a name="28546454"></a>Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. <i>J Am Heart Assoc</i>. 2017;6(6):e004007. doi:10.1161/JAHA.116.004007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28546454/pubmed" id="28546454" target="_blank">28546454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes</i>
<i>Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28605608">
<a name="28605608"></a>Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med</i>. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28605608/pubmed" id="28605608" target="_blank">28605608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495651">
<a name="31495651"></a>Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol</i>. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-6. Erratum in: <i>Lancet Diabetes Endocrinol</i>. 2019;7(12):e23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/31495651/pubmed" id="31495651" target="_blank">31495651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888425">
<a name="28888425"></a>Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. <i>J Diabetes Complications</i>. 2017;31(11):1587-1591. doi:10.1016/j.jdiacomp.2017.07.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28888425/pubmed" id="28888425" target="_blank">28888425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23748505">
<a name="23748505"></a>Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. <i>Postgrad Med</i>. 2013;125(3):33-46. doi:10.3810/pgm.2013.05.2650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/23748505/pubmed" id="23748505" target="_blank">23748505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26041448">
<a name="26041448"></a>O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.<i> Am J Physiol Renal Physiol</i>. 2015;309(3):F227-F234. doi:10.1152/ajprenal.00689.2014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/26041448/pubmed" id="26041448" target="_blank">26041448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26294774">
<a name="26294774"></a>Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. <i>Diabetes Care</i>. 2015;38(9):1638-1642. doi:10.2337/dc15-1380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/26294774/pubmed" id="26294774" target="_blank">26294774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28240446">
<a name="28240446"></a>Tang H, Li D, Zhang J,et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2017;19(8):1106-1115. doi:10.1111/dom.12917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/28240446/pubmed" id="28240446" target="_blank">28240446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26086329">
<a name="26086329"></a>Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2849-2852. doi:10.1210/jc.2015-1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/26086329/pubmed" id="26086329" target="_blank">26086329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30131409">
<a name="30131409"></a>van Niekerk C, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. <i>BMJ</i>
<i>Case Rep</i>. 2018;2018:bcr2017221527. doi:10.1136/bcr-2017-221527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30131409/pubmed" id="30131409" target="_blank">30131409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30415602">
<a name="30415602"></a>Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bexagliflozin-drug-information/abstract-text/30415602/pubmed" id="30415602" target="_blank">30415602</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 140647 Version 40.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
